tislelizumab(neoadjuvant)
Showing 1 - 1 of 1
Head and Neck Squamous Cell Carcinomas Trial in Guanzhou (drug, procedure, radiation)
Recruiting
- Head and Neck Squamous Cell Carcinomas
- Tislelizumab(neoadjuvant)
- +6 more
-
Guanzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Oct 28, 2022